Frontier Science has worked in partnership with the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and in collaboration with Institut de Recherches Internationales SERVIER on the FINESSE trial. The trial was an open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1 ER+ metastatic breast cancer.

Frontier Science’s (Scotland) role involved provision of continuous safety and efficacy reports to all committees charged with oversight of the trial, including international regulatory committees.

This trial is now complete and results were published in Clinical Cancer Research in 2020.

 

OTHER PROJECTS

HERA

HERA

The HERA trial influenced changes in the standard of care for those with HER2-positive breast cancer. Find out more about the study design and our involvement >>

EPoS

EPoS

The EPoS (European Polyp Surveillance) study is a group of related randomised controlled clinical trials which aim to address the optimum colonoscopy surveillance interval for patients who have had premalignant polyps identified and removed from the large bowel, in...

NordICC

NordICC

Colorectal cancer (CRC) is major burden in western countries which develops over a long time-interval from precursor lesions which exist in the colon. Colonoscopy can detect and remove the precursor lesions and may therefore be an effective intervention for the...

WORK WITH US

Frontier Science Scotland provides adaptable solutions across data management and biostatistics for clinical trials. To find out more, get in touch.

data management

biostatistics

quality